Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Andreoni

Showing results (191-200 of 306) with videos related to

Pageof 31
Sort By:
Microorganisms|March 6, 2021
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian CohortVincenzo Malagnino, Elisabetta Teti, Mirko Compagno, et al.
Journal of Global Antimicrobial Resistance|July 23, 2019
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitorsRossana Scutari, Claudia Alteri, Ilaria Vicenti, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2018
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ARTFrancesca Ceccherini-Silberstein, Alessandro Cozzi Lepri, Claudia Alteri, et al.
International Journal of STD & AIDS|January 8, 2025
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohortAndrea Antinori, Giulia Marchetti, Vincenzo Esposito, et al.
Antiviral Therapy|October 26, 2011
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usageValentina Svicher, Claudia Alteri, Anna Artese, et al.
Vaccines|August 26, 2022
Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 VaccineLudovica Ferrari, Mirko Compagno, Laura Campogiani, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 24, 2019
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological successClaudia Alteri, Rossana Scutari, Christof Stingone, et al.
Plos One|May 19, 2017
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Francesca Ceccherini-Silberstein, et al.
Chemotherapy|November 14, 2023
Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic ReviewAndrea Di Lorenzo, Lorenzo Vittorio Rindi, Laura Campogiani, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept studyValeria Cento, Marianna Aragri, Elisabetta Teti, et al.
Pageof 31

Showing results (191-200 of 306) with videos related to

Sort By:
Pageof 31
Microorganisms|March 6, 2021
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian CohortVincenzo Malagnino, Elisabetta Teti, Mirko Compagno, et al.
Journal of Global Antimicrobial Resistance|July 23, 2019
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitorsRossana Scutari, Claudia Alteri, Ilaria Vicenti, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2018
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ARTFrancesca Ceccherini-Silberstein, Alessandro Cozzi Lepri, Claudia Alteri, et al.
International Journal of STD & AIDS|January 8, 2025
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohortAndrea Antinori, Giulia Marchetti, Vincenzo Esposito, et al.
Antiviral Therapy|October 26, 2011
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usageValentina Svicher, Claudia Alteri, Anna Artese, et al.
Vaccines|August 26, 2022
Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 VaccineLudovica Ferrari, Mirko Compagno, Laura Campogiani, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 24, 2019
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological successClaudia Alteri, Rossana Scutari, Christof Stingone, et al.
Plos One|May 19, 2017
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Francesca Ceccherini-Silberstein, et al.
Chemotherapy|November 14, 2023
Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic ReviewAndrea Di Lorenzo, Lorenzo Vittorio Rindi, Laura Campogiani, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept studyValeria Cento, Marianna Aragri, Elisabetta Teti, et al.
Pageof 31